Drug Profile


Alternative Names: Ivacaftor/VX 661; TEZ/IVA; Tezacaftor/ivacaftor; VX-661/ivacaftor; VX-661/VX-770; VX-770/VX-661

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Cyclopropanes; Fluorobenzenes; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Ion channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Cystic fibrosis

Most Recent Events

  • 26 Jul 2017 Preregistration for Cystic fibrosis (In adolescents, In adults) in European Union (PO)
  • 26 Jul 2017 Preregistration for Cystic fibrosis (In adolescents, In adults) in USA (PO)
  • 01 Jun 2017 Vertex completes a phase II trial for Cystic fibrosis in USA (PO) (NCT02508207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top